<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779947</url>
  </required_header>
  <id_info>
    <org_study_id>AM-ESD-001</org_study_id>
    <nct_id>NCT01779947</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo</brief_title>
  <official_title>An Investigator-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, USP 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg and Compare Both Active Treatments to a Placebo Control in Female Subjects With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated With Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amneal Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amneal Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of generic Estradiol Vaginal&#xD;
      Inserts, USP 10 mcg to the reference product Vagifem® 10 mcg and to determined whether the&#xD;
      efficacy of each of the 2 active treatments is superior to that of the placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responders</measure>
    <time_frame>Day 15 (1 day after the administration of the 14th dose of study treatment)</time_frame>
    <description>A responder was defined as a subject with at least a 25% reduction from baseline in the sum of % basal/parabasal and % intermediate cells on vaginal cytology AND vaginal pH &lt; 5.0 with a change from baseline vaginal pH of at least 0.5, where baseline values were collected at Visit 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Success</measure>
    <time_frame>Day 15</time_frame>
    <description>Treatment success was defined as a subject who achieved a score of 0 (none) or 1 (mild) at Visit 3 for the Most Bothersome Symptom (MBS) if her MBS was vaginal dryness, vaginal or vulvar irritation or itching, dysuria or vaginal pain associated with sexual activity, or a result of absence (0) at Visit 3 if her MBS was vaginal bleeding with sexual activity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">519</enrollment>
  <condition>Atrophic Vaginitis Due to Menopause</condition>
  <arm_group>
    <arm_group_label>Estradiol Vaginal Insert 10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estradiol Vaginal Insert 10 mcg - Test Product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vagifem Tablets 10 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vagifem® (Estradiol Vaginal Tablets) 10 mcg - Reference Listed Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for the test product Estradiol Vaginal Tablets 10 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Vaginal Tablets 10 mcg</intervention_name>
    <arm_group_label>Estradiol Vaginal Insert 10 mcg</arm_group_label>
    <arm_group_label>Vagifem Tablets 10 mcg</arm_group_label>
    <other_name>Vagifem®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide and understand written informed consent for the study.&#xD;
&#xD;
          -  Healthy female subject aged 30 to 75 years, inclusive, who was postmenopausal, defined&#xD;
             as having had 12 months of spontaneous amenorrhea or 6 months of spontaneous&#xD;
             amenorrhea with serum follicle-stimulating hormone (FSH) levels &gt; 40 mIU/mL, or 6&#xD;
             weeks postsurgical bilateral oophorectomy with or without hysterectomy.&#xD;
&#xD;
          -  At least 1 subject-assessed moderate to severe symptom of VVA among the following 4&#xD;
             symptoms that was identified by the subject as being most bothersome to her:&#xD;
&#xD;
          -  Vaginal dryness&#xD;
&#xD;
          -  Vaginal and/or vulvar irritation/itching&#xD;
&#xD;
          -  Dysuria&#xD;
&#xD;
          -  Vaginal pain associated with sexual activity OR&#xD;
&#xD;
          -  The presence of vaginal bleeding associated with sexual activity&#xD;
&#xD;
          -  Had ≤ 5% superficial cells on vaginal smear cytology at Visit 1.&#xD;
&#xD;
          -  Vaginal pH &gt; 5.0 at Visit 1.&#xD;
&#xD;
          -  Systolic blood pressure ≤ 150 mm Hg and diastolic blood pressure ≤ 90 mm Hg at Visit&#xD;
             1.&#xD;
&#xD;
          -  If &gt; 40 years old, documentation of a negative mammogram (obtained at Visit 1 or&#xD;
             within 9 months prior to Visit 1). A radiology report documenting a negative mammogram&#xD;
             must have been available and must have been taken within 9 months of Visit 1 or&#xD;
             obtained at Visit 1.&#xD;
&#xD;
          -  Normal clinical breast examination at Visit 1.&#xD;
&#xD;
          -  For women with intact uterus, vaginal ultrasonography confirmation at Visit 1 of an&#xD;
             inactive endometrial lining, with an endometrial thickness &lt; 4 mm.&#xD;
&#xD;
          -  Documented Pap smear conducted within the previous 12 months of Visit 1 with no&#xD;
             findings that the investigator believed would contraindicate the use of topical&#xD;
             vaginal estradiol.&#xD;
&#xD;
          -  In general good health with no clinically significant disease other than symptoms of&#xD;
             VVA that might have interfered with the study evaluations.&#xD;
&#xD;
          -  Was willing and able to understand and comply with the requirements of the study,&#xD;
             including applying the medication as instructed, returning for the required study&#xD;
             visits, complying with therapy prohibitions, and able to complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to estradiol vaginal tablet or any component of the study&#xD;
             medication.&#xD;
&#xD;
          -  A subject who had received any treatment listed below more recently than the indicated&#xD;
             washout period prior to Visit 1/Screening/Baseline.&#xD;
&#xD;
          -  Prohibited Medications - (Washout Period Prior to Visit 1/Screening/Baseline)&#xD;
&#xD;
          -  Vaginal lubricants or moisturizers - (at least 48 hours (2 days))&#xD;
&#xD;
          -  Vaginal hormonal products (rings, creams, gels) - (at least 1 week (7 days))&#xD;
&#xD;
          -  Transdermal estrogen alone or estrogen/progestin products - (at least 4 weeks (28&#xD;
             days))&#xD;
&#xD;
          -  Oral estrogen and/or progestin therapy - (at least 8 weeks (56 days))&#xD;
&#xD;
          -  Intrauterine progestin therapy - (at least 8 weeks (56 days))&#xD;
&#xD;
          -  Progestin implants and estrogen alone injectable drug therapy - (at least 3 months (90&#xD;
             days))&#xD;
&#xD;
          -  Estrogen pellet therapy or progestin injectable drug therapy - (at least 6 months (180&#xD;
             days))&#xD;
&#xD;
          -  Subject who had engaged in sexual intercourse within 48 hours (2 days) of Visit 1.&#xD;
&#xD;
          -  Screening mammogram or clinical breast examination results indicating any suspicion of&#xD;
             breast malignancy.&#xD;
&#xD;
          -  History of undiagnosed vaginal bleeding.&#xD;
&#xD;
          -  Known bleeding disorder.&#xD;
&#xD;
          -  History of significant risk factors for endometrial cancer (i.e., tamoxifen use, prior&#xD;
             pelvic radiation therapy, and endometrial hyperplasia).&#xD;
&#xD;
          -  For women with an intact uterus, screening vaginal ultrasonography showing endometrial&#xD;
             thickness of ≥ 4 mm.&#xD;
&#xD;
          -  Known, suspected, or history of breast cancer or cervical cancer.&#xD;
&#xD;
          -  Known or suspected estrogen-dependent neoplasia.&#xD;
&#xD;
          -  History of uncontrolled hypertension.&#xD;
&#xD;
          -  Active deep vein thrombosis, pulmonary embolism, or history of these conditions.&#xD;
&#xD;
          -  Active arterial thromboembolic disease (e.g., stroke or myocardial infarction) or a&#xD;
             history of these conditions.&#xD;
&#xD;
          -  Known liver dysfunction or disease.&#xD;
&#xD;
          -  Known anaphylactic reaction or angioedema to estradiol vaginal tablets.&#xD;
&#xD;
          -  Known protein C, protein S, antithrombin deficient, or other known thrombophilic&#xD;
             disorders. - Active vaginal herpes simplex infection or any known concurrent vaginal&#xD;
             infections.&#xD;
&#xD;
          -  Abnormal Pap smear within the previous 12 months of Visit 1 or obtained during Visit&#xD;
             1. Any evidence of malignancy or premalignant changes or atypical squamous cell of&#xD;
             undetermined significance (ASCUS) Pap smear with positive high risk human&#xD;
             papillomavirus (HPV).&#xD;
&#xD;
          -  Any clinically significant condition or situation (including laboratory values) other&#xD;
             than the condition being studied that, in the opinion of the investigator, would have&#xD;
             interfered with the study evaluations or optimal participation in the study.&#xD;
&#xD;
          -  Use of any investigational drugs or device within 30 days of signing the ICF.&#xD;
&#xD;
          -  Current participation in any other clinical study involving an investigational drug or&#xD;
             device.&#xD;
&#xD;
          -  Consumed excessive amounts of alcohol, abused drugs, or had any condition that would&#xD;
             have compromised compliance with this protocol.&#xD;
&#xD;
          -  Previous participation in this study.&#xD;
&#xD;
          -  Subjects who, in the opinion of the Investigator, would have been non-compliant with&#xD;
             the requirements of the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Todd Kays, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Amneal Pharmaceuticals, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Affiliated Research center, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montogmery Women's Health Associates</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Care Research Corp.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James A. Simon, MD PC/ Women's Health and Research Consultants</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Reserach</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Age Medical Reserach Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta North Gynecology</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Clinical Research, LLC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center. LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Health Care</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Women's Health and Wellness, LLC/ Women's Health Research Center</name>
      <address>
        <city>Plainsboro</city>
        <state>New Jersey</state>
        <zip>08536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawthorne Medical Research, Inc.</name>
      <address>
        <city>Winstom-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Center for Women;s Health Reserach</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Philadelphia, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seatlle Womne's Health,Reserach, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>January 28, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <disposition_first_submitted>June 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 26, 2014</disposition_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Atrophic Vaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 30, 2021</submitted>
    <returned>May 21, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

